Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC5A2 | P31639 | 11/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084926 | 0.90 | MTNR1A (0.62) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL30630312 | 0.90 | MTNR1A (0.62) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL27085180 | 0.85 | SLC5A2 (0.66) | MTNR1AMTNR1BSLC5A2SLC5A1 | |
| SCHEMBL27084751 | 0.82 | HTR6 (0.57) | SLC28A3ATMSLC5A2SLC5A1 | |
| SCHEMBL27085189 | 0.81 | SLC5A2 (0.52) | SLC28A3ATMSLC5A2SLC5A1 | |
| SCHEMBL27084827 | 0.81 | SLC5A2 (0.52) | SLC28A3ATMSLC5A2SLC5A1 | |
| SCHEMBL25101135 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BATMMEN1CYP1A2 | |
| SCHEMBL30295239 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BATMMEN1CYP1A2 | |
| SCHEMBL25101193 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BATMMEN1CYP1A2 | |
| SCHEMBL30295385 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BATMMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| CN-117120415-A | Modified indole alkaloids for therapeutic use | 指南针探路者有限公司 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | MTNR1A 40/4885MTNR1B 89/4885SLC28A3 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.